Association Between Genetic Polymorphisms and Type 2 Asthma in Children

NCT06840717 | Recruiting DMC

• 1 other identifier: GuangzhouIRD-CLY
• Study Type: observational
• Target: 300
• Locations: 1 country
• Sites: 1

Brief Summary

To further understand the role of gene single nucleotide polymorphism (SNP) in the occurrence of type 2 inflammation-related asthma in children by analyzing the gene single nucleotide polymorphism (SNP), lung function and type 2 inflammation indicators of children diagnosed with asthma in outpatient and inpatient. To provide a theoretical basis for the study of personalized treatment and prevention strategies for asthma.

Conditions

Asthma in Children; Genetic Disease; Inflammation

Keywords

cytokines; Single nucleotide polymorphism; type 2 inflammation; ashtma; Susceptibility

Outcome Measures

Primary Outcomes (3)

• type 2 inflammation indicators

  Fraction of exhaled nitric oxide(FeNO)、Blood eosinophil count、Percentage of sputum eosinophils and Serum total immunoglobulin E

  Outpatient visits for the first time

• pulmonary function indicators

  Forced expiratory volume in one second(FEV1)、Forced vital capacity(FVC)、Ratio of forced expiratory volume in one second to forced vital capacity(FEV1/FVC) and Peak expiratory flow(PEF)

  Outpatient visits for the first time

• single nucleotide polymorphism

  Differences in SNPs of genes detected in children's blood samples

  Outpatient visits for the first time

Study Arms (2)

Case group

Diagnosis of asthma children

Control group

Physical health of children

Eligibility Criteria

• Age: 3 Years - 14 Years
• Gender Eligibility Details: There was no significant difference in the ratio of male to female between the case and control groups
• Healthy Volunteers: Yes
• Age Groups: Child (0-17)
• Sampling Method: Non-Probability Sample

Study Population

Children with asthma, aged 3-14 years, attending our hospital.

You may qualify if:

• All children with asthma diagnosis accord with the GINA in 2023 edition;
• Other diseases that could cause wheezing and cough were excluded, such as acute laryngitis, diphtheria, congenital airway abnormalities, and tracheal foreign bodies;
• In front of the hospital 2 weeks without antibiotics, systemic hormone medication history;
• There were no other complications, such as congenital heart disease, pneumonia, gastroesophageal reflux disease, muscle dysplasia, etc.

You may not qualify if:

• Children who had taken immunosuppressants, antibiotics and other drugs for a long time before admission;
• Children with primary immunodeficiency disease;
• The children and their families failed to cooperate or refused the experimental observation.

Sponsors & Collaborators

• Guangzhou Institute of Respiratory Disease: lead

Study Sites (1)

Guangzhou institute of respiratory disease

Guangzhou, Guangdong, 510120, China

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

For children enrolled in this study, 2ml EDTA anticoagulated whole blood was retained

MeSH Terms

Conditions

Genetic Diseases, Inborn; Inflammation; Disease Susceptibility

Condition Hierarchy (Ancestors)

Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Disease Attributes

Central Study Contacts

Lihong Sun, M.D.

CONTACT

13719240285; sunlihong9797@126.com

Lanying Cheng

CONTACT

15918742726; chenglanyingmed@163.com

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Target Duration: 1 Year
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: October 3, 2024
• First Posted: February 21, 2025
• Study Start: January 30, 2024
• Primary Completion: December 30, 2025
• Study Completion: December 30, 2025
• Last Updated: February 21, 2025

Record last verified: 2025-02

Locations

CN (1)